

pLVX-DD-ZsGreen1 Control

Catalog No(s). **Amount Lot Number** 631752 (Not sold separately). 20 μg pLVX-DD-ZsGreen1 Control Vector (500 ng/μl) Specified on product label. Sold as part of 631751.

pLVX-DD-ZsGreen1 Control Vector Information




Figure 1. pLVX-DD-ZsGreen1 Control vector map.

Clontech Laboratories, Inc.

A Takara Bio Company

1290 Terra Bella Avenue, Mountain View, CA 94043, USA

Asia Pacific

U.S. Technical Support: tech@clontech.com

800.662.2566 Late update: July 12, 2011

United States/Canada

Europe Japan +1.650.919.7300+33.(0)1.3904.6880 +81.(0)77.543.6116

pLVX-DD-ZsGreen1 Control

Location of Features

- 5' LTR: 1-635
- PBS (primer binding site): 636–653
- Ψ (packaging signal): 685–822
- RRE (Rev-response element): 1303–1536
- cPPT/CTS (central polypurine tract/central termination sequence): 2028–2151
- $P_{\text{CMV IE}}$ (human cytomegalovirus immediate early promoter): 2185–2788
- DD (FKBP-L106P destabilization domain): 2881–3204
- ZsGreen1 (Zoanthus sp. green fluorescent protein): 3211–3903
- P_{PGK} (phosphoglycerate kinase promoter): 3914–4422
- Puro (puromycin resistance gene): 4443–5042
- WPRE (woodchuck hepatitis virus posttranscriptional regulatory element): 5056–5647
- 3' LTR: 5851–6487
- pUC origin of replication: 6957–7627 (complementary)
- Amp^r (ampicillin resistance gene; β-lactamase): 7772–8768 (complementary)

NOTICE TO PURCHASER:

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, in vitro diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without prior written approval of Clontech Laboratories, Inc.

Your use of this product is also subject to compliance with the licensing requirements listed below and described on the product's web page at http://www.clontech.com. It is your responsibility to review, understand and adhere to any restrictions imposed by these statements.

Last update: July 12, 2011 Page 2 of 2